FDA accepts Eisai's subcutaneous Leqembi filing, sets January 25 decision date

About a month after Eisai initiated a rolling FDA application for its subcutaneous form of Leqembi, the U.S. agency has accepted the filing.

And with that rubber stamp, Eisai's SC form of its much-hyped Alzheimer's drug has a date with FDA destiny: January 25, 2025, according to a Monday release.